1028PMirvetuximab soravtansine, a folate receptor alpha...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

1028PMirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

O'Malley, D, Richardson, D, Vergote, I B, Gilbert, L, Martin, L P, Mantia-Smaldone, G M, Castro, C, Provencher, D, Matulonis, U A, Malek, K, Moore, K N
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz250.036
Date:
October, 2019
File:
PDF, 96 KB
2019
Conversion to is in progress
Conversion to is failed